“…The mutations of ClC-1 associated with myotonia congenita can be correlated to anomalous gating-permeation or reduced ClC-1 protein abundance at the plasma membrane (Lee et al, 2013;Jeng et al, 2020). This distinction, together with the new and important advance in knowledge of the mechanisms behind proteostasis (Peng et al, 2016), biogenesis (Chen et al, 2015) and those governing trafficking to the surface membrane (Peng et al, 2018), has opened the doors to the novel pharmacological approach for increasing ClC-1 in plasma membrane (Altamura et al, 2018;Jeng et al, 2020). By studying the biophysical mechanism to induce an increase of ClC-1 in plasma membrane, certain inhibitors of ligase E3 (Lee et al, 2013) or blockers of ubiquitin inhibitors (Chen et al, 2015) are emerging.…”